

Journal Pre-proof

Systematic Review of Acceptability, Cardiovascular, Neurological, Bone Health, and HRT Outcomes following Risk Reducing Surgery in *BRCA* carriers

Faiza Gaba, Ranjit Manchanda

PII: S1521-6934(20)30018-3

DOI: <https://doi.org/10.1016/j.bpobgyn.2020.01.006>

Reference: YBEOG 2005

To appear in: *Best Practice & Research Clinical Obstetrics & Gynaecology*

Received Date: 9 November 2019


Revised Date: 19 January 2020

Accepted Date: 21 January 2020

Please cite this article as: Gaba F, Manchanda R, Systematic Review of Acceptability, Cardiovascular, Neurological, Bone Health, and HRT Outcomes following Risk Reducing Surgery in *BRCA* carriers, *Best Practice & Research Clinical Obstetrics & Gynaecology*, <https://doi.org/10.1016/j.bpobgyn.2020.01.006>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.



**Systematic Review of Acceptability, Cardiovascular, Neurological, Bone Health, and HRT Outcomes
following Risk Reducing Surgery in *BRCA* carriers**

AUTHORS

Faiza Gaba,^{1,2} Ranjit Manchanda^{1,2,3}

¹Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

²Department of Gynaecological Oncology, St Bartholomew's Hospital, London, UK, EC1A 7BE

³MRC Clinical Trials Unit, University College London, 90 High Holborn, London, UK WC1V 6LJ

Corresponding author:

Dr Ranjit Manchanda

E-mail: r.manchanda@qmul.ac.uk

ABSTRACT

Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) is the most effective option and gold standard for ovarian cancer (OC) risk-reduction, particularly given the absence of an effective national OC screening programme. However, premenopausal RRSO leads to premature surgical menopause with detrimental long-term health sequelae particularly in women who do not/are unable to take hormone replacement therapy (HRT). HRT uptake in women undergoing pre-menopausal oophorectomy appears low and is dependent on informed counselling, on the safety of HRT and efficacy in mitigating the health sequelae of premature menopause. Acceptance of a central role for the fallopian tube in OC etiopathogenesis coupled with detrimental consequences of premature menopause, has led to the attractive proposal of early-salpingectomy with delayed oophorectomy as an alternative OC surgical prevention strategy in premenopausal women who have completed their family but decline or wish to delay RRSO. The successful implementation of risk reducing surgery for OC prevention depends on acceptability of surgery to both recipients (e.g. *BRCA1/BRCA2* carriers) and intervention deliverers (healthcare professionals/researchers). Acceptability is also informed by an understanding of health outcomes following risk reducing surgery and the safety of HRT. It is therefore vital to understand the effects of surgery on important health outcomes such as cardiovascular health, neurological function and bone health. We present a comprehensive review of acceptability, selected health outcomes above and HRT safety following risk reducing surgery.

KEYWORDS

Targeted surgical prevention; RRSO; RRESO; ovarian cancer; *BRCA*; acceptability

INTRODUCTION

Targeted surgical prevention of ovarian cancer

BRCA1/BRCA2 carriers have a ~17%-44% risk of ovarian cancer (OC) and ~65-72% risk of breast cancer (BC).¹⁻⁴ Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) is the most effective option and gold standard for OC risk-reduction, particularly given the absence of an effective national OC screening programme. Premenopausal RRSO leads to premature surgical menopause which has detrimental long-term health sequelae (increased risk of heart disease, osteoporosis, vasomotor symptoms, sexual dysfunction, neurocognitive decline) especially if unable to use hormone-replacement-therapy (HRT) due to a personal history of BC.⁵⁻¹³ RRSO is typically offered from ages 35–40 years for *BRCA1*-carriers and 40–45 years for *BRCA2*-carriers. Decision making is affected by numerous factors. It is a complex and dynamic process and timing needs to be individualised following informed counselling. Much of the literature used to counsel high risk women on the effects of oophorectomy on cardiovascular health, bone health and neurological function is derived from the low risk population. There are many misperceptions on the safety of HRT use in *BRCA* carriers and the counselling received by patients from clinicians is known to be inconsistent.

Acceptance of a central role for the fallopian tube in OC etiopathogenesis coupled with detrimental consequences of premature menopause, has led to risk-reducing early-salpingectomy and delayed oophorectomy (RRESDO) as an attractive two-step alternative OC surgical-prevention strategy in pre-menopausal women who have completed their family but decline or wish to delay RRSO. RRESDO provides some level of risk-reduction whilst conserving ovarian function and avoiding negative health effects of premature menopause. Lack of clarity on several key issues supports offering RRESDO solely within a research setting. Extent of OC-risk reduction and long-term health outcomes with early-salpingectomy including on ovarian-function/premature-menopause remain

unclear. Salpingectomy will not prevent OC arising outside the fallopian tube. Residual fimbrial tissue implants on the ovarian surface after salpingectomy are reported in 9.8% cases,¹⁴ and could become a potential site for malignant transformation. Etiopathogenesis of OC is complex and our current understanding incomplete. Serous-tubular-intraepithelial-carcinoma (STIC) has been described but the natural history, progression-rates, outcomes and rate-limiting step in development of OC associated with different types is unknown.¹⁵ STICs may not be precursors to all HGSOE cases.¹⁶ Concerns exist regarding attrition from delayed-oophorectomy. A proportion who miss delayed-oophorectomy may develop OC. Uncertainties remain around cost-effectiveness. There is also the potential for increased morbidity resulting from two surgeries instead of one.

Acceptability and its importance

Successful implementation of risk-reducing surgery for OC-prevention depends on acceptability of surgery to both recipients (*BRCA1/BRCA2*-carriers) and intervention deliverers (healthcare professionals/researchers).^{17, 18} If it is considered acceptable, *BRCA1/BRCA2*-carriers are more likely to adhere to recommendations and benefit from improved clinical-outcomes. From the healthcare professionals perspective, if delivery of risk-reducing surgery to *BRCA1/BRCA2*-carriers has low acceptability, surgery may not be delivered as intended (by intervention designers), impacting overall effectiveness of the strategy. The references to 'acceptability' in UK Medical-Research-Council (MRC) guidance documents on appropriate methods for designing and evaluating complex interventions¹⁹⁻²¹ has increased over the years reflecting its growing importance in healthcare, rising from nil in 2000 to fourteen-times in 2015. For the purpose of this review we have measured acceptability in terms of surgical uptake.

We conducted a systematic review on acceptability of 'risk reducing surgery', the effects of surgery on cardiovascular/bone/neurological health and the safety of HRT in *BRCA1/BRCA2* carriers to aid clinicians in counselling high risk women faced with the decision as to whether or not to undergo surgery.

METHODOLOGY

Search-strategy and selection-criteria

Five databases were searched from inception to January-2019 using a common search-strategy (supplementary-table-1): Pubmed, Medline, Embase, CINAHL and PsycINFO. Additionally we searched web-based platforms including specialised journals, Google-searches for grey-literature, conference-proceedings and clinical-trial registries (ISRCTN-registry/ClinicalTrials.gov registry). Searches were not restricted by geographical location, publication-year or study-design, but limited to human studies and English-language. The search was re-run prior to final analyses to capture recently published studies.

Reference-lists of publications retrieved were screened and transferred into reference-management software (EndNote-X8.2, Clarivate-Analytics). Titles/abstracts were screened followed by retrieval and screening of full-text articles fulfilling eligibility-criteria.

Predefined inclusion-criteria were *BRCA1/BRCA2*-carriers undergoing RRSO or RRESO. Outcome-measures were: uptake; cardiovascular health; bone health; neurological health; HRT-uptake, safety and efficacy (in alleviating the health consequences of premature menopause).

Exclusions included abstracts/studies that included participants with a personal history of OC, mismatch-repair mutation-carriers (*MLH1/MSH2/MSH6*) and individuals at population level OC-risk.

Data-extraction, Quality-assessment and Analysis

Data were extracted using a standardised, predesigned formatted-sheet (following piloting and refinement) in Microsoft-Excel 2013. Four main categories of data were extracted: methodological characteristics, study-population, surgical-interventions (RRSO/RRESDO), reported outcome-measures. Risk of bias was assessed using the MINORS (Methodological-Index for Non-Randomized-Studies) checklist. Higher scores indicated greater quality studies. No studies were excluded from data synthesis based on quality-assessment scores. We tabulated characteristics and reported outcome-measures of all studies for qualitative synthesis.

RESULTS AND COMMENTARY

Supplementary-figure-1 provides the flow-chart outlining search outcomes and the study-selection process. Searches of electronic databases and reference-lists generated 3547 references. On evaluation of titles and abstracts, 612 articles were potentially eligible for detailed assessment, and 67 met our inclusion-criteria for qualitative-synthesis. Tables 1-3 summarise relevant-studies.

Uptake of surgery

Forty-one studies report on uptake of risk-reducing surgery for OC-prevention in *BRCA1/BRCA2* carriers (Table-1). 39/41²²⁻⁶⁰ investigate RRSO uptake and 2/41 RRESDO^{61, 62} uptake. Intention to undergo RRSO before *BRCA* carrier status confirmed (putative uptake) ranges from 16-94%^{45, 55, 57} and actual uptake (following confirmation of *BRCA* carrier status) ranges from 12-78%.^{34-42, 44-49, 51-59, 61-68} RRSO uptake is higher amongst Caucasian population,³⁹ *BRCA1* (vs *BRCA2*) carriers,^{38, 43, 54, 63, 64} older women^{38, 45, 63, 68} and women with a personal history of BC.^{35, 68, 69} RRSO uptake rates may vary by ethnicity/country.^{41 70 28, 30} Both similar and lower surgical prevention rates for RRSO (and risk

reducing mastectomy (RRM)) have been reported in Jewish women, while one study even reports higher RRSO rates (54% v 41%, respectively).^{28, 41} It is well recorded that black and minority ethnic (BME) populations experience barriers to accessing healthcare.⁷⁰ The same appears to be true amongst BME *BRCA* carriers accessing RRSO. In Cragun et al, uptake of RRSO amongst black and Caucasian women was found to be 28% and 77% respectively.³⁹ The slightly higher overall RRSO uptake observed in *BRCA1* (42-76%) than *BRCA2*-carriers (28-70%)^{32, 38, 43, 54, 63, 64} may be due to the higher lifetime-risk of OC with *BRCA1*. Higher uptake amongst older *BRCA*-carriers^{38, 45, 63, 68} suggests that despite OC-risk, many women prefer to delay RRSO until after completing childbearing),⁷¹ the preference of some to delay this till after menopause and the impact of age on risk. 44-72% *BRCA*-carriers undergoing RRSO have a personal history of BC.^{35, 68, 69} The positive association of history of BC with RRSO uptake may be linked to earlier reports of reduction in contralateral BC-risk^{72, 73} (although recent literature does not support this)^{74, 75} and reduction in BC-specific mortality,⁷⁵⁻⁷⁸ diagnosis of *BRCA*-status following BC, along with personal preferences.

In contrast to earlier reports suggesting *BRCA*-carriers undergo surgery within 12-months of their *BRCA*-result,⁵¹ three time-to-event analyses now show that RRSO-uptake is dynamic and increases with time continuing months/years after initial ascertainment/*BRCA*-diagnosis. 24-38% of *BRCA*-carriers undergo surgery >12months after their initial counselling appointment following results of genetic-testing.^{34, 37, 68} Unfortunately, most studies (18/32) do not report mean time from ascertainment of *BRCA*-status to RRSO making it difficult to determine the impact on uptake of RRSO at different time-points or the impact of publication of international RRSO guidelines or key publications on OC/BC-risk and detrimental health sequelae of premature menopause on RRSO rates.

Three longitudinal studies measuring both putative and actual uptake,^{45, 55, 57} show actual uptake is lower than putative uptake. Reasons for this discrepancy in uptake were not properly explored.

A pilot prospective, multicentre, non-randomised US study investigating acceptability, surgical outcomes, QoL and psychosocial outcomes of RRESDO as an alternative to RRSO or OC screening, has reported RRESDO uptake as 44% (19/43) and RRSO uptake as 28% (12/43).⁶¹ It is possible that offering pre-menopausal women who have completed their family RRESDO could reduce uptake of pre-menopausal RRSO but may increase the overall number of women undergoing pre-menopausal OC surgical prevention as it offers an alternative option to individuals otherwise declining oophorectomy due to the negative consequences of premature menopause.

Bone health

Reported incidence of osteoporosis and osteopenia diagnosed on DEXA scans in *BRCA* carriers following RRSO (both pre and post-menopausal) is 8-14% and 23-57% respectively (table-2).^{6, 65, 79-82} Pre-menopausal RRSO in *BRCA* carriers using E-HRT (oestrogen-HRT) is not associated with an increased risk of osteoporosis/osteopenia. Challberg et al in a retrospective cohort study, found the incidence of osteoporosis and osteopenia to be higher in *BRCA* carriers with no E-HRT use after pre-menopausal RRSO in comparison to women who took E-HRT (osteoporosis: 13% vs 3%, osteopenia: 33% vs 13%).⁸³ In a Dutch prospective cohort study, bone mass density (BMD) was not found to be lower in *BRCA* carriers undergoing RRSO (pre and post-menopausal) in comparison to an age-matched reference population who had not undergone oophorectomy.⁶ However 47% of carriers had a history of E-HRT use and this was not adjusted for in the analysis.⁶ Although a prospective cohort study by Cohen et al, evaluated differences between the incidence of osteoporosis/osteopenia in *BRCA* carriers undergoing pre or post-menopausal RRSO, the numbers in

the analysis (n=30) are too small to draw any meaningful conclusion.⁸⁰ Overall reported outcomes are in line with findings that E-HRT preserves BMD. Evidence from general population studies show that BMD declines at a significantly greater rate following oophorectomy (trabecular bone loss from the spine 12-19% in the first year) than women who undergo natural menopause (2.5% in the first year).⁸⁴ This BMD loss appears to slow down in women using E-HRT following pre-menopausal oophorectomy.

Atraumatic fracture risk post RRSO is 4%.⁶⁵ In a prospective cohort study, RRSO in *BRCA* carriers was not found to be associated with an increased risk of atraumatic fracture and this has also been found to be the case in the prospective, observational Nurses' Health Study of 29,380 women at population level risk of OC followed up for twenty-four years.^{6, 85} However a prospective Dutch cohort study found a significant increase in bone turnover markers (BTMs): osteocalcin, procollagen type-I N-terminal peptide and serum C-telopeptide of type-I collagen, which have been linked to future fracture risk, at ≥ 2 years after RRSO, in *BRCA* carriers aged <50 years compared to carriers >50.⁷ However, BTMs have limited clinical utility.⁸⁶ It is not routinely recommended to use BTMs to select individuals at risk of fractures.⁸⁶

Cardiovascular health

The majority of data pertaining to cardiovascular health following oophorectomy are derived from the low risk population and are used to counsel premenopausal high risk women considering RRSO. Studies have reported premenopausal oophorectomy is associated with an increased risk of coronary heart disease (CHD),^{12, 13, 85, 87} with an up to 3% absolute increase in mortality from CHD described in women who have early surgical menopause and do not take HRT.¹² This is in keeping with data suggesting that oestrogens have a cardio-protective effect before menopause, and that

reduction of this protection increases the risk of cardiovascular disease. Although an increased risk of stroke has been reported, this is not statistically significant (HR 1.14, 95%CI 0.98-1.33).^{85,88}

Metabolic syndrome (MetS) has multiple definitions. Key metabolic abnormalities include glucose intolerance, insulin resistance, central obesity, dyslipidaemia and hypertension.⁸⁹ In a European prospective cohort study, Hu et al. followed 6156 men and 5356 women aged 30–89 years for a median of 8.8 years.⁹⁰ Among women, MetS implied an increased risk of death from all causes (HR 1.38, 95% CI 1.02-1.87) and of death from CVD (HR 2.78, 95% CI 1.57-4.94).⁹⁰ Postmenopausal status has been found to be associated with a 60% increased risk of MetS, after adjusting for age, BMI, income and physical inactivity.⁹¹ Data are scarce regarding the association between surgical menopause and MetS. An association between premenopausal oophorectomy performed for benign pathology in women at population level risk of OC and MetS was demonstrated by Dørum et al.⁹² They found that patients with bilateral oophorectomy before 50 years of age (n= 263) had a higher prevalence of MetS than age-matched controls (n=789) in a Norwegian population-based health study (38% vs 30% respectively).⁹²

Data on CHD following premenopausal oophorectomy in *BRCA* carriers is limited (table-2). A Norwegian case-control study by Michelsen et al compared CHD risk profile (total cholesterol, HDL cholesterol, blood pressure, BMI, waist circumference) and Framingham risk score of cases (326 *BRCA* carriers and women with a strong FH of OC who have undergone RRSO) and age matched controls (1630 women at population level risk of OC who had not undergone oophorectomy). Baseline cardiovascular morbidity did not differ significantly between cases and controls in terms of prevalence of angina, myocardial infarction, stroke, diabetes mellitus or smoking. Results show cases had a statistically significantly improved CHD risk profile (lower total cholesterol level, higher HDL cholesterol level, lower systolic blood pressure, lower BMI) and lower Framingham total point score

than controls following adjustment for personal history of cancer, education, employment status, cohabitation status, HRT use and level of physical activity. These findings linking RRSO with a favourable CHD profile must be interpreted with caution due to the small sample size and because the comparator group was made up of women at general population risk of OC. Positive health seeking behaviour amongst *BRCA* carriers has been documented in the literature⁹³ which may have resulted in an improved CHD profile (akin to a healthy volunteer effect) thereby confounding the results.

In a prospective cohort study, Cohen et al (n=226) found no statistically significant difference in hypertension, diabetes mellitus, hypercholesterolaemia, CHD or MI in *BRCA* carriers undergoing pre or post-menopausal RRSO.⁸⁰ However HRT use in pre-menopausal women in that study was only 8%. Advancing age is an independent risk factor for cardiovascular disease⁹⁴ and in this study may be a confounder as there was a fifteen year difference between the mean ages of women undergoing pre and post-menopausal RRSO (42 vs 57 years).⁸⁰ Also, there were no baseline measurements for comparison, no control group and the follow-up period short (39 months).⁸⁰

Michelsen et al concluded that *BRCA* carriers undergoing RRSO had a more favourable CHD profile than controls (women at population level risk of OC who had not undergone oophorectomy),⁹⁵ women undergoing RRSO were significantly more likely to develop MetS (OR 2.12 95%CI 1.26-3.57, P=0.005).⁹⁶ The suggested explanation by the authors is the omission of central obesity when evaluating CHD (but included when evaluating MetS) resulted in a more favourable CHD profile in *BRCA* carriers who had undergone RRSO.⁹⁵

There is no data on the effects of RRESDO on cardiovascular health or MetS.

Neurological function

There are no data on neurological function post RRSO/RRESO in *BRCA* carriers. However there is data from women at general population level risk of OC. The Mayo Clinic Cohort Study of Oophorectomy and Aging included women who underwent pre-menopausal oophorectomy (n=2390) and a group of referent women (n=2390) who did not undergo oophorectomy. Both groups were followed up (median 29.5 years) with the same combination of active and passive methods (direct or proxy interviews, medical records in a records-linkage system, death certificates).⁹⁻¹¹ Data show a statistically significant increased risk of dementia in women undergoing bilateral oophorectomy ≤ 48 years who do not receive E-HRT until the age of 50 (HR 1.89, 95%CI 1.27–2.83, $p=0.002$).⁹ In women who undergo bilateral oophorectomy ≤ 48 years but who do receive E-HRT, there is no increased risk of dementia (HR 0.79, 95%CI 0.25–2.54, $p=0.69$).⁹ In the same cohort, there is a non-statistically significant increase in the risk of parkinsonism and Parkinson's disease (PD) in women undergoing pre-menopausal bilateral oophorectomy ≤ 48 years (HR 2.00, 95%CI 0.97–4.15, $p=0.06$).¹⁰ However, again in this same cohort study, women who underwent bilateral oophorectomy ≤ 45 years have been found to have an increased all-cause mortality (HR 1.67, 95%CI 1.16–2.40, $p=0.006$) as well as mortality specifically associated with neurologic and psychiatric disorders (HR 6.28, 95%CI 1.83–21.5, $p=0.003$).¹¹ These findings may suggest that the HRs for parkinsonism/PD could be underestimated if the women who died were at increased risk of parkinsonism/PD (selective censoring). However PD findings from the Mayo Clinic Cohort study are in keeping with other studies including the Nurses' Health Study (n= 77,713) which have shown that bilateral oophorectomy is not associated with an increased risk of PD.^{97, 98}

Hormone replacement therapy safety and uptake

Several observational studies have evaluated effect of HRT on BC risk in *BRCA* carriers (table-3).⁹⁹⁻¹⁰⁵ Mean duration of HRT use reported varies from 3.6–7.6 years.⁹⁹⁻¹⁰⁵ Short term HRT use following RRSO in *BRCA1/BRCA2* carriers has not been shown to significantly increase BC risk.^{99-101, 103-105} However sample sizes of these studies are small, follow up short, there is a paucity of data amongst HRT use in *BRCA2* carriers and there are no RCT data.

Authors of the Women's Health Initiative (WHI) Randomized Trials reported an increased risk of developing BC amongst post-menopausal women aged 50-79 years at population level risk of OC in the E+P (oestrogen and progestogen) HRT arm of the trial (HR 1.24, 95%CI 1.01-1.53), and a non-significant reduction in risk among women in the E-HRT group (HR 0.79, 95%CI 0.61-1.02).¹⁰⁶ The Million Women Study (MWS – observational prospective cohort) reported a significantly increased BC risk in post-menopausal women aged 50-64 at population level risk of OC in women using E-HRT (RR 1.30, 95%CI 1.21-1.40, $p < 0.0001$), and E+P-HRT (RR 2.00, 95%CI 1.88-2.12, $p < 0.0001$).¹⁰⁷ However these results are not generalizable to *BRCA* carriers who are a younger cohort of women undergoing premature/surgical menopause as a result of RRSO and have a different (higher) inherent BC risk profile.

Data in *BRCA* carriers have not shown a significant difference in BC risk between E-alone and E+P preparations.^{100, 103, 104} A recent multi-centre prospective cohort study (n=872) has shown that progesterone containing HRT (E+P HRT/P-HRT) use following RRSO in *BRCA1* carriers <45 years, resulted in a non-significant increase in BC for each year of progesterone containing HRT use (HR 1.14, 95%CI 0.90-1.46, $P = 0.28$).¹⁰² However the number of women using progesterone containing HRT was small (n=62), menopause status at time of RRSO was not reported, HRT use was determined via patient self-administered questionnaires, 10% of the study sample was lost to follow up and birth cohort effect was not adjusted for. Overall, results of this study are not enough to

change current clinical practice which is to recommend use of short term HRT until the age of fifty-one (average age of menopause) in BC unaffected *BRCA1/BRCA2* carrier undergoing premenopausal RRSO. In women with triple negative BC, HRT may be considered for short-term use following premenopausal RRSO on a case-by-case basis, particularly with good prognostic disease following a multidisciplinary team review involving breast oncologists and menopause specialists.

There are no data on effects of short-term HRT post RRSO until age of natural menopause on endometrial cancer risk in *BRCA* carriers. However the WHI showed a non-significant decrease in the risk of endometrial cancer following E+P HRT use (HR 0.81, 95%CI 0.48-1.36).¹⁰⁶

HRT use in *BRCA* carriers undergoing pre-menopausal RRSO improves discomfort/dyspareunia and vaginal dryness but does not improve sexual pleasure, habit, satisfaction or libido.^{83, 108-110} Although HRT improves certain symptoms of sexual dysfunction, these symptoms are not improved to pre-surgical levels.^{109, 110} HRT reduces prevalence and severity of hot flushes following pre-menopausal RRSO.^{83, 108, 109, 111} HRT use has also been shown to be protective against bone loss in both pre-menopausal *BRCA* carriers following RRSO⁸³ as well as women at population level risk of OC^{112, 113} and is protective against hip and total fractures in the general population.¹⁰⁶ There is no data on the efficacy of HRT in preventing ischaemic heart disease in *BRCA* carriers undergoing pre-menopausal RRSO. However data from observation studies indicate that HRT reduces the incidence of ischemic heart disease in women at population level risk undergoing premature menopause.^{13, 114, 115} HRT use has also been shown to improve QoL following RRSO in *BRCA* carriers.¹⁰⁸⁻¹¹⁰

HRT uptake in *BRCA* carriers after pre and post-menopausal RRSO is reported to be between 6-82% (table-3).^{54, 57, 104, 111, 116} Specifically uptake of HRT in women undergoing premenopausal RRSO is 8-

75%.^{80, 108-110, 117} This wide variation and potentially low uptake rates in premenopausal women is concerning bearing in mind that HRT mitigates the risks of heart disease, osteoporosis, neurocognitive decline, vasomotor symptoms and sexual dysfunction in *BRCA* carriers undergoing premenopausal RRSO.

For *BRCA* carriers undergoing post-menopausal RRSO, HRT uptake is between 0-10%.^{80, 110} There is limited data from a case-control studies by Eisen et al (OR 0.68, 95%CI 0.37-1.27, $p=0.22$) and Kotsopoulos et al (OR 0.72, 95%CI 0.44–1.18, $p=0.20$)¹⁰³ indicating that HRT use following natural menopause does not increase the risk of BC. However sample size for these studies were small and there was no subgroup analysis performed on the effect of type or preparation of HRT on BC risk. Clinicians must be cautious in using systemic HRT in *BRCA* carriers who have reached natural menopause. This is not routinely recommended given paucity and limitations of data in *BRCA* carriers and the findings of the WHI and MWS studies which could potentially impact older *BRCA* carriers who have reached natural menopause.

SUMMARY

Acceptability of targeted surgical prevention of OC is a multifaceted, fluid and dynamic concept that evolves with time and is informed and influenced by counselling received from clinicians on health outcomes following surgery and the safety of HRT. RRSO remains gold standard for preventing OC in *BRCA* carriers with uptake being higher in *BRCA1* carriers, Caucasians, women who have completed childbearing and women with a personal history of BC. However when performed in premenopausal *BRCA* carriers it increases risk of osteoporosis/osteopenia, CHD and neurocognitive decline (though *BRCA* specific data on CHD and neurocognitive impact are limited). Use of HRT until natural menopause mitigates risks and there is data supporting safety of short term HRT use in *BRCA* carriers

without a personal history of receptor positive BC. However despite this, HRT uptake in women undergoing premenopausal RRSO remains low highlighting a pressing need for greater education of health professionals on safety of HRT which will in turn improve the accuracy of counselling received by *BRCA* carriers. Acceptance of the central role of the fallopian tube in etiopathogenesis of OC together with health consequences of premature menopause associated with oophorectomy has led to RRESO being proposed as a two-step surgical alternative for pre-menopausal women who have completed their family but decline or wish to delay oophorectomy. Due to unknown implications of RRESO on long term health, extent of OC risk reduction and concerns over attrition, it is recommended that it is only offered within the context of a research trial.

ACKNOWLEDGEMENTS

No funding was received for this review.

CONFLICT OF INTEREST

FG is an investigator and study coordinator for the PROTECTOR study. RM declares research funding from Barts and The London Charity and Roseetrees Trust for the PROTECTOR Study and is Chief Investigator. RM declares research funding from The Eve Appeal, Cancer Research UK and from Barts & the London Charity outside this work, as well as an honorarium for grant review from Israel National Institute for Health Policy Research. RM is supported by a NHS Innovation Accelerator Fellowship.

PRACTICE POINTS

- Risk reducing salpingo-oophorectomy is the gold standard for ovarian cancer prevention in *BRCA1* and *BRCA2* carriers. It has high acceptability, though a wide range of uptake rates are reported in the literature.
- Risk reducing early salpingectomy and delayed oophorectomy is a surgical alternative available solely within the context of a research trial for pre-menopausal women declining/wishing to delay oophorectomy.
- Hormone replacement therapy is recommended following premenopausal oophorectomy until the age of fifty-one in women without a personal history of breast cancer. It may be considered in receptor negative breast cancer on a case by case basis.
- Hormone replacement therapy minimises the detrimental consequences of premature menopause.

RESEARCH AGENDA

- Factors affecting the uptake of postmenopausal risk reducing salpingo-oophorectomy in *BRCA1* and *BRCA2* carriers.
- Impact of premenopausal RRSO on CHD and neurocognitive function in BRCA carriers
- Hormone replacement therapy and risk of breast cancer in breast cancer unaffected *BRCA2* carriers undergoing pre-menopausal salpingo-oophorectomy.
- Effect of premenopausal RRSO with and without HRT on fracture risk

REFERENCES

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet.* 2003 May;72(5):1117-30.
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol.* 2007 Apr 10;25(11):1329-33.
3. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *Jama.* 2017 Jun 20;317(23):2402-16.
4. Evans DG, Shenton A, Woodward E, Laloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. *BMC Cancer.* 2008;8:155.
5. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. *Obstetrics and gynecology.* 2013 Apr;121(4):709-16.
6. Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, et al. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. *European journal of cancer (Oxford, England : 1990).* 2015 Feb;51(3):400-8.
7. Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, et al. Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. *PLoS one.* 2017;12(1):e0169673.
8. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. *Menopause Int.* 2008 Sep;14(3):111-6.
9. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. *Neurology.* 2007 Sep 11;69(11):1074-83.
10. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. *Neurology.* 2008 Jan 15;70(3):200-9.
11. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ, 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. *The Lancet Oncology.* 2006 Oct;7(10):821-8.
12. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. *Menopause (New York, NY).* 2006 Mar-Apr;13(2):265-79.
13. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Jr., Roger VL, Melton LJ, 3rd, et al. Increased cardiovascular mortality after early bilateral oophorectomy. *Menopause.* 2009 Jan-Feb;16(1):15-23.
14. Gan C, Chenoy R, Chandrasekaran D, Brockbank E, Hollingworth A, Vimplis S, et al. Persistence of fimbrial tissue on the ovarian surface after salpingectomy. *American journal of obstetrics and gynecology.* 2017 Oct;217(4):425.e1-.e16.
15. Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, et al. Evidence for a Dualistic Model of High-grade Serous Carcinoma: BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma. *Am J Surg Pathol.* 2015 Jan 9.
16. Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, et al. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. *Cancer Discov.* 2016 Dec;6(12):1342-51.

17. Diepeveen S, Ling T, Suhrcke M, Roland M, Marteau TM. Public acceptability of government intervention to change health-related behaviours: a systematic review and narrative synthesis. *BMC Public Health*. 2013 2013/08/15;13(1):756.
18. Stok FM, de Ridder DT, de Vet E, Nureeva L, Luszczynska A, Wardle J, et al. Hungry for an intervention? Adolescents' ratings of acceptability of eating-related intervention strategies. *BMC Public Health*. 2016 Jan 5;16:5.
19. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. *BMJ (Clinical research ed)*. 2000;321(7262):694-6.
20. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *Bmj*. 2008 Sep 29;337:a1655.
21. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. *BMJ : British Medical Journal*. 2015;350:h1258.
22. Antill Y, Reynolds J, Young MA, Kirk J, Tucker K, Bogtstra T, et al. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. *European journal of cancer (Oxford, England : 1990)*. 2006 Mar;42(5):621-8.
23. Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2009 Aug;18(8):2318-24.
24. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. *Clinical breast cancer*. 2007 Dec 2007;7(11):875-82.
25. Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D. Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia. *Current oncology (Toronto, Ont)*. 2019 Feb;26(1):e17-e23.
26. Harmsen MG, Arts-de Jong M, Horstik K, Manders P, Massuger L, Hermens R, et al. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. *Gynecol Oncol*. 2016 Oct;143(1):113-9.
27. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *The New England journal of medicine*. 2002 May 2002;346(21):1609-15.
28. Laitman Y, Vaisman Y, Feldman D, Helpman L, Gitly M, Paluch Shimon S, et al. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. *Clinical genetics*. 2014 Jan;85(1):68-71.
29. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. *J Clin Oncol*. 2005 Oct 1;23(28):6890-8.
30. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. *Br J Cancer*. 2019 Jul;121(1):15-21.
31. Phillips KA, Jenkins MA, Lindeman GJ, McLachlan SA, McKinley JM, Weideman PC, et al. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Clinical genetics*. 2006 Sep;70(3):198-206.
32. Sidon L, Ingham S, Clancy T, Clayton R, Clarke A, Jones EA, et al. Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. *Br J Cancer*. 2012 Feb 14;106(4):775-9.

33. Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. *Am J Obstet Gynecol*. 2013 Apr;208(4):329.e1-6.
34. Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brondum-Nielsen K, Waldstrom M, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. *Clinical genetics*. 2010 Apr;77(4):342-9.
35. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. *Genetic testing and molecular biomarkers*. 2009 Feb 2009;13(1):51-6.
36. Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. *American journal of medical genetics Part A*. 2003 Apr 30;118a(3):201-9.
37. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. *Genetics in medicine : official journal of the American College of Medical Genetics*. 2008 Mar 2008;10(3):161-6.
38. Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. *Breast cancer research and treatment*. 2014;148(2):397-406.
39. Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. *Cancer*. 2017;123(13):2497-505.
40. D'Alonzo M, Pecchio S, Liberale V, Modaffari P, Biglia N, Piva E, et al. Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. *Clinical Breast Cancer*. 2018 Dec 2018;18(6).
41. Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(12):1321-8.
42. Flippo-Morton T, Walsh K, Sarantou T, White RL, Chambers K, Amacker-North L, et al. Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature. *Breast Journal*. 2016 Jan 2016;22(1):35-44.
43. Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, et al. Risk management options elected by women after testing positive for a BRCA mutation. *Gynecol Oncol*. 2014 Feb;132(2):428-33.
44. Kim SI, Lim MC, Lee DO, Seo SS, Kang S, Park SY, et al. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. *Journal of Cancer Research and Clinical Oncology*. 2016 Jan 2016;142(1):333-40.
45. Kram V, Peretz T, Sagi M. Acceptance of Preventive Surgeries by Israeli Women Who had Undergone BRCA Testing. *Familial Cancer*. 2006 2006/11/01;5(4):327-35.
46. Kwong A, Wong CH, Shea C, Suen DT, Choi CL. Choice of management of southern Chinese BRCA mutation carriers. *World journal of surgery*. 2010 Jul;34(7):1416-26.
47. Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. *Preventive medicine*. 2000 Jul;31(1):75-80.
48. Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JGM, Seynaeve C, et al. One Year Follow-Up of Women Opting for Presymptomatic Testing for BRCA1 and BRCA2: Emotional Impact of the Test Outcome and Decisions on Risk Management (Surveillance or Prophylactic Surgery). *Breast Cancer Research and Treatment*. 2002 2002/05/01;73(2):97-112.
49. Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among

high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*. 2017;145(1):122-9.

50. Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. *Bjog*. 2012 Jan 20.
51. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. *Lancet (London, England)*. 2000 Jun 10;355(9220):2015-20.
52. Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, et al. Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. *Open medicine : a peer-reviewed, independent, open-access journal*. 2007;1(2):e92-e8.
53. Metcalfe KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. *Journal of medical genetics*. 2000 Nov 2000;37(11):866-74.
54. Pezaro C, James P, McKinley J, Shanahan M, Young MA, Mitchell G. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. *Fam Cancer*. 2012 Sep;11(3):403-10.
55. Ray JA, Loescher LJ, Brewer M. Risk-reduction surgery decisions in high-risk women seen for genetic counseling. *Journal of genetic counseling*. 2005 Dec 2005;14(6):473-84.
56. Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. *Cancer*. 2012 Jan 15;118(2):510-7.
57. Tiller K, Meiser B, Butow P, Clifton M, Thewes B, Friedlander M, et al. Psychological Impact of Prophylactic Oophorectomy in Women at Increased Risk of Developing Ovarian Cancer: A Prospective Study. *Gynecologic Oncology*. 2002 2002/08/01;86(2):212-9.
58. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. *Cancer*. 2006 Dec 15;107(12):2745-51.
59. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, et al. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. *Cancer*. 2011 Jun 2011;117(12):2659-67.
60. Julian-Reynier C, Mancini J, Mouret-Fourme E, Gauthier-Villars M, Bonadona V, Berthet P, et al. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. *European journal of human genetics : EJHG*. 2011 May;19(5):500-6.
61. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. *Gynecologic oncology*. 2018;150(1):79-84.
62. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. *Gynecologic oncology*. 2014 May 2014;133(2):283-6.
63. Evans DGR, Lalloo F, Shenton A, Clancy T, Hopwood P, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. *Cancer Epidemiology Biomarkers and Prevention*. 2009 Aug 2009;18(8):2318-24.
64. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. *Clin Breast Cancer*. 2007 Dec;7(11):875-82.
65. Garcia C, Lyon L, Conell C, Littell RD, Powell CB. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy. *Gynecol Oncol*. 2015 Sep;138(3):723-6.

66. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med*. 2002 May 23;346(21):1609-15.
67. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. *Journal of Clinical Oncology*. 2005 2005/10/01;23(28):6890-8.
68. Manchanda R, Burnell M, Johnson M, Sharma A, Gessler S, Side L, et al. Factors influencing uptake and timing of risk reducing salpingo- oophorectomy in women at risk of familial ovarian cancer: A competing risk time to event analysis. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2012 Apr 2012;119(5):527-36.
69. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, et al. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. *Obstetrics and gynecology*. 2006 Sep;108(3 Pt 1):515-20.
70. Szczipura A. Access to health care for ethnic minority populations. *Postgraduate Medical Journal*. 2005;81(953):141.
71. Cherry C, Ropka M, Lyle J, Napolitano L, Daly MB. Understanding the needs of women considering risk-reducing salpingo-oophorectomy. *Cancer nursing*. 2013 May-Jun;36(3):E33-E8.
72. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *British journal of cancer*. 2011 Apr 2011;104(9):1384-92.
73. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2004 Jun 2004;22(12):2328-35.
74. Basu NN, Ingham S, Howell A, Evans DG, Hodson J, Lalloo F, et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. *Familial Cancer*. 2015 Aug 2015;14(4):531-8.
75. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA: Journal of the American Medical Association*. 2010 Sep 2010;304(9):967-75.
76. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Lancet Oncology*. 2006 Mar 2006;7(3):223-9.
77. Huzarski T, Byrski T, Gronwald J, Górski B, Domagała P, Cybulski C, et al. Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. *Journal of Clinical Oncology*. 2013 2013/09/10;31(26):3191-6.
78. Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *JAMA oncology*. 2015 Jun 2015;1(3):306-13.
79. Chapman JS, Powell CB, McLennan J, Crawford B, Mak J, Stewart N, et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. *Gynecol Oncol*. 2011 Aug;122(2):339-43.
80. Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. *Fam Cancer*. 2012 Mar;11(1):69-75.
81. Michelsen TM, Dorum A, Trope CG, Fossa SD, Dahl AA. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2009 Aug;19(6):1029-36.
82. Powell CB, Alabaster A, Stoller N, Armstrong MA, Salyer C, Hamilton I, et al. Bone loss in women with BRCA1 and BRCA2 mutations. *Gynecologic oncology*. 2018 Mar;148(3):535-9.

83. Challberg J, Ashcroft L, Laloo F, Eckersley B, Clayton R, Hopwood P, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. *British journal of cancer*. 2011;105(1):22-7.
84. Gallagher JC. Effect of early menopause on bone mineral density and fractures. *Menopause (New York, NY)*. 2007 May-Jun;14(3 Pt 2):567-71.
85. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. *Obstet Gynecol*. 2009 May;113(5):1027-37.
86. Wheeler G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. *Journal of translational medicine*. 2013;11:201-.
87. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. *Obstetrics and gynecology*. 2013;121(4):709-16.
88. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term Mortality Associated with Oophorectomy versus Ovarian Conservation in the Nurses' Health Study. *Obstetrics and gynecology*. 2013;121(4):709-16.
89. Cooper-DeHoff RM, Pepine CJ. Metabolic syndrome and cardiovascular disease: challenges and opportunities. *Clinical cardiology*. 2007;30(12):593-7.
90. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. *Archives of internal medicine*. 2004 May 24;164(10):1066-76.
91. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Archives of internal medicine*. 2003 Feb 24;163(4):427-36.
92. Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2). *Gynecologic Oncology*. 2008 2008/06/01;109(3):377-83.
93. Heshka JT, Pallechi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. *Genetics In Medicine*. 2008 01/01/online;10:19.
94. Dhingra R, Vasan RS. Age as a risk factor. *The Medical clinics of North America*. 2012;96(1):87-91.
95. Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010 Feb;20(2):233-9.
96. Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study. *European Journal of Cancer*. 2009;45(1):82-9.
97. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. *Neurology*. 2003 Mar 11;60(5):790-5.
98. Ragonese P, D'Amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. *Neurology*. 2004 Jun 8;62(11):2010-4.
99. Domchek S, Kaunitz AM. Use of systemic hormone therapy in BRCA mutation carriers. *Menopause (New York, NY)*. 2016 Sep;23(9):1026-7.
100. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. *J Natl Cancer Inst*. 2008 Oct 1;100(19):1361-7.

101. Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. *Climacteric : the journal of the International Menopause Society*. 2016 Oct;19(5):419-22.
102. Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. *JAMA Oncol*. 2018 Aug 1;4(8):1059-65.
103. Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. *Breast Cancer Res Treat*. 2016 Jan;155(2):365-73.
104. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol*. 2005 Nov 1;23(31):7804-10.
105. Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N. The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. *BMC women's health*. 2017 Mar 21;17(1):22.
106. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama*. 2002 Jul 17;288(3):321-33.
107. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet (London, England)*. 2003 Aug 9;362(9382):419-27.
108. Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy. *Maturitas*. 2016 Mar;85:42-8.
109. Madalinska JB, van Beurden M, Bleiker EMA, Valdimarsdottir HB, Hollenstein J, Massuger LF, et al. The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy. *Journal of Clinical Oncology*. 2006 2006/08/01;24(22):3576-82.
110. Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. *Gynecologic Oncology*. 2011 2011/04/01;121(1):163-8.
111. Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. *Psycho-oncology*. 2013 Jan;22(1):212-9.
112. Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. *Clinical endocrinology*. 2010 Dec;73(6):707-14.
113. Prior JC, Vigna YM, Wark JD, Eyre DR, Lentle BC, Li DK, et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 1997 Nov;12(11):1851-63.
114. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. *The Journal of clinical endocrinology and metabolism*. 2004 Aug;89(8):3907-13.
115. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. *Maturitas*. 2006 Jan 20;53(2):226-33.
116. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. *Gynecologic oncology*. 2016 Jan 2016;140(1):101-6.

117. Vermeulen RFM, Beurden Mv, Kieffer JM, Bleiker EMA, Valdimarsdottir HB, Massuger LFAG, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. *European Journal of Cancer*. 2017 2017/10/01/;84:159-67.

Journal Pre-proof

Table-1: Studies reporting uptake of surgical prevention in BRCA carriers

Study	Country	Study design	Sample size (n)	Population	Type of risk reducing surgery	Study findings	Time from ascertainment of carrier status to RRS	Risk of bias
Antill, 2006 ¹	Australia	Prospective cohort	266	BRCA1/BRCA2 carriers	RRSO	Uptake overall: 17.3%	3.73 years (mean)	22/24
Beattie, 2009 ²	US	Retrospective cohort	272	BRCA1/BRCA2 carriers	RRSO	Uptake 51% (122/272)	3.7 years (median)	11/16
Botkin, 2003 ³	US	Prospective cohort	26	BRCA1 carriers	RRSO	Uptake overall: 46% (12/26) Uptake by age: 25-39 years 29% (5/17), >40 years 78% (7/9)	NR	22/24
Bradbury, 2008 ⁴	US	Retrospective cohort	88	BRCA1/BRCA2 carriers	RRSO	Uptake 70% (62/88);	NR	17/24
Chai, 2014 ⁵	US, UK, Austria, Netherlands, Canada, Israel (PROSE consortium)	Prospective cohort	1499	BRCA1/BRCA2 carriers	RRSO	BRCA1 <50 years 86% BRCA1 >50 years 13% BRCA2 <50 years 71% BRCA2 >50 years 22%	NR	22/24
Cragun, 2017 ⁶	US	Retrospective cohort	?	BRCA1/BRCA2 carriers	RRSO	Black 28% (32/ Hispanic 91% (11/ Non-Hispanic white 77% (47/	NR	19/24
D'Alonzo, 2018 ⁷	Italy	Retrospective cohort	79	BRCA1/BRCA2 carriers	RRSO	Uptake 53% (42/79)	NR	11/16
Evans, 2009 ⁸	UK	Prospective cohort	211	BRCA1/BRCA2 carriers	RRSO	Overall uptake: 45% (96/211) Uptake by mutation status: BRCA1 52% (43/211), BRCA2 28% (29/211) Uptake by age BRCA1/BRCA2: <35 years 12% (8/67), 35-45 years 60% (50/84), >45 years 28% (14/50)	4 years (median)	15/16
Finkelman, 2012 ⁹	US, UK, Austria, Netherlands, Canada, Israel (PROSE consortium)	Prospective cohort	4649	BRCA1/BRCA2 carriers	RRSO	Uptake in Jewish women: 54% (522/969) Uptake in non Jewish women 41% (1502/3680)	NR	23/24
Flippo-Morton, 2016 ¹⁰	US	Retrospective cohort	87	BRCA1/BRCA2 carriers	RRSO	Uptake 78% (68/87)	3.3 years	13/16
Friebel, 2007 ¹¹	US, UK, Austria	Prospective cohort	537	BRCA1/BRCA2 carriers	RRSO	BRCA1 42% (143/339) BRCA2 38% (76/198)	BRCA1 0.9 years (mean) BRCA2 1.5 years	14/16

							(mean)	
Garcia, 2014 ¹²	US	Retrospective cohort	305	BRCA1/BRCA2 carriers	RRSO	Overall uptake 74% (225/305) Uptake by BRCA status: BRCA1 76% (130/170), BRCA2 70% (95/135)	0.5 years (median)	14/16
Hanley, 2019 ¹³	Canada	Retrospective cohort	885	BRCA1/BRCA2 carriers	RRSO	BRCA1: 64.7% BRCA2: 62.2%	2 years	20/24
Harmsen, 2016 ¹⁴	Netherlands	Retrospective cohort	580	BRCA1/BRCA2 carriers	RRSO	BRCA1: 98.5% BRCA2: 97.5%	NR	20/24
Holman, 2014 ¹⁵	US	Prospective cohort	204	BRCA1/BRCA2 carriers	RRESDO	Expressed intention to undergo RRESDO: 34%	NR	15/16
Kauff, 2002 ¹⁶	US	Retrospective cohort	170	BRCA1/BRCA2 carriers	RRSO	Uptake 58% (98/170)	0.3 years (mean)	22/24
Kim, 2016 ¹⁷	South Korea	Retrospective cohort	42	BRCA1/BRCA2 carriers	RRSO	52% (22/42)	7.3 months (mean)	14/16
Kram, 2006 ¹⁸	Israel	Retrospective cohort survey study	43	Jewish BRCA1/BRCA2 founder mutation carriers	RRSO	Considered RRSO before genetic result 31%; considered RRSO after genetic result 94% Overall actual uptake 78% Actual uptake by age: <50 years 44%, >50 years 89%	NR	14/16
Kwong, 2010 ¹⁹	Hong Kong	Retrospective cohort	28	BRCA1/BRCA2 carriers	RRSO	Uptake 14% (4/28)	NR	13/16
Laitman, 2014 ²⁰	Israel	Prospective cohort	179	BRCA1/BRCA2 carriers	RRSO	Uptake 49% in Jewish women	NR	20/24
Lerman, 2000 ²¹	US	Prospective cohort	39	BRCA1/BRCA2 carriers	RRSO	Uptake 13% (5/39)	NR	20/24
Lodder, 2002 ²²	Netherlands	Retrospective cohort	26	BRCA1/BRCA2 carriers	RRSO	Uptake 50% (13/26)	1 year	20/24
Madalinska, 2005 ²³	Netherlands	Retrospective cohort	369	BRCA1/BRCA2 carriers or at increased risk because of FH of OC	RRSO	Uptake 72% (265/368)	NR	21/24
Mai, 2017 ²⁴	US, Australia	Prospective cohort	2287	BRCA1/BRCA2 carriers or strong FH of OC	RRSO	Uptake 40% (904/2287)	NR	21/24
Manchanda, 2012 ²⁵	UK	Prospective cohort	1133	BRCA1/BRCA2 (290) carriers and UMS women (873)	RRSO	Uptake 55% in BRCA carriers over 5 years	5 years (mean)	16/16
Meijers-	Netherlands	Retrospective cohort	45	BRCA1/BRCA2	RRSO	Uptake 64% (29/45)	1.75 years	22/24

Heijboer, 2000 ²⁶				carriers			(median)	
Metcalfe, 2000 ²⁷	Canada	Retrospective cohort	56	BRCA1/BRCA2 carriers	RRSO	54% (30/56)	1.4 years (mean)	13/16
Metcalfe, 2007 ²⁸	Canada	Retrospective cohort	672	BRCA1/BRCA2 carriers	RRSO	Uptake 54% (363/672)	4 years (mean)	23/24
Metcalfe, 2019 ²⁹	10 countries*	Prospective cohort	6223	BRCA1/BRCA2 carriers	RRSO	Uptake overall: 64.7% (4023/6223) BRCA1: 62.8% BRCA2: 69.7%	7.5 years (mean)	23/24
Nebgen, 2018 ³⁰	US	prospective, cohort, pilot study	43	Pre-menopausal BRCA1/BRCA2 carriers	RRESO/RRSO	Uptake: RRESO 44% (19/43), RRSO 28% (12/43)	NR	22/24
Pezaro, 2012 ³¹	Australia	Retrospective cohort	276	BRCA1/BRCA2 carriers	RRSO	Uptake: 57% (157/276) Uptake by mutation status: BRCA1 63% (83/142), BRCA2 51% (74/144)	NR	22/24
Phillips, 2006 ³²	Australia	Prospective cohort	70	BRCA1/BRCA2 carriers	RRSO	Uptake overall: 29%	3 years	21/24
Ray, 2005 ³³	US	Prospective cross-sectional	62	BRCA1/BRCA2 carriers or strong FH of OC	RRSO	Intended uptake: 16% (9/58) Actual uptake: 21% (13/62)	NR	14/16
Reynier, 2011 ³⁴	France	Prospective cohort	101	BRCA1/BRCA2 carriers	RRSO	Uptake overall: 38%	5 years	21/24
Schwartz, 2012 ³⁵	US	Retrospective cohort	100	BRCA1/BRCA2 carriers	RRSO	Uptake 65% (65/100)	5.3 years (mean)	15/16
Sidon, 2012 ³⁶	UK	Retrospective cohort	732	BRCA1/BRCA2 carriers	RRSO	BRCA1: 54.5% BRCA2: 45.5%	5 years	22/24
Singh, 2013 ³⁷	US	Retrospective cohort	136	BRCA1/BRCA2 carriers	RRSO	Uptake overall 52%	Range 1-11 years	20/24
Skytte, 2010 ³⁸	Denmark	Retrospective cohort	306	BRCA1/BRCA2 carriers	RRSO	Uptake 75%	10 years	15/16
Tiller, 2002 ³⁹	Australia	Prospective cohort	83	BRCA1/BRCA2 carriers or at increased risk because of FH of OC	RRSO	Expressed intention to undergo RRSO at baseline: 24% (20/83) would opt for RRSO, 29% (24/83) would decline RRSO, 47% (39/83) unsure; Actual uptake at 3 years: 5/20, 0/24, 5/39	NR	24/24
Uyei, 2006 ⁴⁰	US	Retrospective cohort	132	BRCA1/BRCA2 carriers	RRSO	Uptake 36% (48/132)	NR	13/16
Westin, 2011 ⁴¹	US	Retrospective cohort	182	BRCA1/BRCA2 carriers or	RRSO	Uptake 34% (62/182)	NR	21/24

strong FH of OC

NR – not reported, RRSO – risk reducing salpingo-oophorectomy, RRESDO – risk reducing early salpingectomy with delayed oophorectomy, OC – ovarian cancer, UMS- unknown mutation status

*Austria, Canada, China, France, Israel, Italy, Norway, Holland, Poland, USA

Journal Pre-proof

Table-2: Studies reporting bone and cardiovascular health following surgical prevention in BRCA carriers

Studies	Country	Study design	Sample size (n)	Population	Type of risk reducing surgery	Outcomes	Reported outcome measures	Follow up	Risk of bias
Challberg, 2011 ⁴²	UK	Retrospective cohort	119	BRCA1/BRCA2 carriers or strong FH of OC	RRSO	Osteoporosis; osteopenia	osteopenia 28% osteoporosis 10%	NR	20/24
Chapman, 2011 ⁴³	US	Prospective cohort	51	BRCA1/BRCA2 carriers	RRSO	Osteoporosis; osteopenia	Osteopenia: 23% (7/31) Osteoporosis: 10% (3/31)	6 years (median)	21/24
Cohen, 2012 ⁴⁴	US	Prospective cohort	226	BRCA1/BRCA2 carriers	RRSO	Osteopenia; osteoporosis; diabetes mellitus; hypercholesterolaemia; CAD/MI;	Pre-menopausal RRSO osteopenia: 61% (54/88); post-menopausal RRSO osteopenia: 52% (33/64) Pre-menopausal RRSO osteoporosis: 9% (8/88); post-menopausal RRSO osteoporosis: 20% (13/64) Pre-menopausal RRSO diabetes mellitus: 1% (1/88); post-menopausal RRSO diabetes mellitus: 4% (3/64) Pre-menopausal RRSO hypercholesterolaemia: 15% (21/88); post-menopausal RRSO hypercholesterolaemia: 18% (15/64) Pre-menopausal RRSO CAD/MI: 1% (2/88); post-menopausal RRSO CAD/MI: 4% (3/64)	NR	20/24
Fakkert, 2015 ⁴⁵	Netherlands	Prospective cohort	211	BRCA1/BRCA2 carriers or strong FH of OC	RRSO	Osteoporosis; osteopenia	osteopenia: 42% (89/211) osteoporosis: 6% (13/211) Women with RRSO at premenopausal age did not have lower BMD and higher fracture incidences compared to an age-matched population	5 years	20/24
Fakkert, 2017 ⁴⁶	Netherlands	Prospective cohort	211	BRCA1/BRCA2 carriers or strong FH of OC	RRSO	Fracture risk	increase in bone turnover measured after RRSO which are linked to future fracture risk	5 years	20/24
Garcia, 2015 ⁴⁷	US	Retrospective cohort	225	BRCA1/BRCA2 carriers	RRSO	Osteoporosis; osteopenia; fractures	osteopenia 55.6% osteoporosis 12.1% Fracture post RRSO: 4% (10/225). RRSO in <i>BRCA</i> carriers was not found to be associated with an increased risk of atraumatic	41 months (median)	22/24

							fractures.		
Michelsen, 2009 ⁴⁸	Norway	Retrospective case-control	338 cases (RRSO), 1690 controls (no RRSO)	BRCA1/BRCA2 carriers or strong FH of OC (cases), BRCA status unknown for controls	RRSO	Osteoporosis	osteoporosis 8 vs. 3%; (p = 0.02) in cases vs controls	6.5 years (mean)	22/24
Michelsen, 2009 ⁴⁹	Norway	Retrospective case-control	326 cases (RRSO), 679 controls (no RRSO)	BRCA1/BRCA2 carriers or strong FH of OC (cases), BRCA status unknown for controls	RRSO	Metabolic syndrome	RRSO significantly associated with metabolic syndrome according to the 2005 National Cholesterol Education Program Adult Treatment Panel III criteria (OR 2.46 [95% CI 1.63-3.73]) and according to the International Diabetes Federation criteria (OR 2.49 [95%CI 1.60-3.88])	6.5 years (mean)	22/24
Michelsen, 2010 ⁵⁰	Norway	Retrospective case-control	326 cases (RRSO), 1630 controls (no RRSO)	BRCA1/BRCA2 carriers or strong FH of OC (cases), BRCA status unknown for controls	RRSO	CHD	Except for a wider waist circumference, cases had a more favourable CHD risk profile including more physical activity, lower levels of total cholesterol (5.8 vs 6.3 mmol/L), higher levels of high-density lipoprotein cholesterol (1.7 vs 1.5 mmol/L), lower systolic blood pressure (128 vs 139 mmHg), and lower BMI (25 vs 27 kg/m ²) compared with controls Cases had a lower mean (SD) Framingham total score compared to the controls (12.9 [5.1] vs 14.5 [5.2]; P = 0.02)	6.5 years (mean)	22/24
Powell, 2018 ⁵¹	US	Prospective cohort	238	BRCA1/BRCA2 carriers	RRSO	Osteoporosis	Premenopausal RRSO: 13% Postmenopausal RRSO: 17%	NR	21/24

NR – not reported, RRSO – risk reducing salpingo-oophorectomy, RRESDO – risk reducing early salpingectomy with delayed oophorectomy, OC – ovarian cancer, CHD – coronary heart disease, BMD – bone mass density

Table-3: Studies reporting hormone replacement therapy uptake, safety and efficacy in BRCA carriers

Studies	Country	Study design	Sample size (n)	Population	Type of risk reducing surgery	Outcomes	Reported outcome measures	Follow up	Risk of bias
Challberg, 2011 ⁴²	UK	Retrospective cohort	119	BRCA1/BRCA2 carriers or strong FH of OC	RRSO	HRT efficacy	Less sexual dysfunction in HRT use vs no HRT use group ($p=0.09$) Fewer vasomotor symptoms in HRT use group vs past use or never use ($p= 0.03$) Reduced incidence of osteoporosis/osteopenia on DEXA scans with HRT use vs no use (osteopenia 13% vs 33%, osteoporosis 3% vs 13%)	NR	20/24
Cohen, 2012 ⁴⁴	US	Prospective cohort	226	BRCA1/BRCA2 carriers	RRSO	HRT uptake	Pre-menopausal HRT uptake: 8% (11/144); post-menopausal HRT uptake: 0% (0/82)	NR	20/24
D'Alonzo, 2018 ⁷	Italy	Retrospective cohort	79	BRCA1/BRCA2 carriers	RRSO	HRT uptake	HRT uptake post RRSO 21% (9/42)	NR	11/16
Eisen, 2008 ⁵²	Canada	Retrospective case-control	236 cases (HRT use), 236 controls (no HRT use)	BRCA1 carriers	N/A	HRT safety	OR for breast cancer associated with ever use of HRT compared with never use was 0.58 (95% CI = 0.35 to 0.96; $P = .03$).	4 years	21/24
Finch, 2011 ⁵³	Canada	Prospective cohort	114	BRCA1/BRCA2 carriers	RRSO	HRT uptake, HRT efficacy	HRT uptake: pre-menopausal RRSO 39% (29/75), postmenopausal RRSO 10% (4/39) Less sexual dysfunction in HRT use vs no HRT use group ($p=0.015$) Fewer vasomotor symptoms in HRT use vs no HRT use group ($p=0.0003$) Greater QoL in HRT use vs no use group as measured by the MENQOL questionnaire	1 year	22/24
Finch, 2013 ⁵⁴	Canada	Prospective cohort	96	BRCA1/BRCA2 carriers	RRSO	HRT uptake	HRT uptake 30% (29/96)	1 year	21/24
Johansen, 2016 ⁵⁵	Norway	Retrospective, case-control	294 cases (RRSO), 1224 controls (no RRSO)	BRCA1/BRCA2 carriers or strong FH of OC (cases), BRCA status unknown for controls	RRSO	HRT uptake	HRT uptake 44% (119/294)	NR	21/24
Kotsopoulos, 2016 ⁵⁶	Canada	Retrospective	432 cases	BRCA1	N/A	HRT safety	The adjusted OR for breast cancer comparing all	4 years	21/24

		case-control	(breast cancer), 432 controls (no breast cancer)	carriers			women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24)		
Kotsopoulos, 2018 ⁵⁷	Canada	Prospective cohort	872	BRCA1 carriers	N/A	HRT safety	HR 0.97 (95%CI 0.62-1.52; P=0.89) for ever use of any type of HRT vs no use HR 0.73 (95%CI 0.41-1.32; p=0.30) for ever use of E-HRT vs no use HR 1.31 (0.66-2.57; P=0.44) for ever use of E+P HRT vs no use	7.6 years (mean)	21/24
Madalinska, 2006 ⁵⁸	Netherlands	Retrospective cohort	164	BRCA1/BRCA2 carriers or at increased risk because of FH of OC	RRSO	HRT uptake; HRT efficacy	Pre-menopausal HRT uptake post RRSO 38% (63/164) RRSO HRT users group reported significantly fewer symptoms overall than RRSO HRT nonusers group (P<0.05) RRSO HRT users and RRSO HRT non users groups reported comparable levels of sexual functioning. Compared with the GS group, the RRSO HRT users group reported significantly more discomfort during sexual activities (P<0.01).	NR	21/24
Nebgen, 2018 ³⁰	US	prospective, cohort, pilot study	43	Pre-menopausal BRCA1/BRCA2 carriers	RRESO/RRSO	HRT uptake (RRSO arm only)	Pre-menopausal HRT uptake in RRSO arm: 2/43 (5%)	12 months	22/24
Pezaro, 2012 ³¹	Australia	Retrospective cohort	276	BRCA1/BRCA2 carriers	RRSO	HRT uptake	HRT uptake 6% (10/157)	5 years (median)	22/24
Rebbeck, 2005 ⁵⁹	US	Prospective cohort	462	BRCA1/BRCA2 carriers	RRSO	HRT safety	HRT of any type after RRSO did not significantly alter the reduction in breast cancer risk associated with RRSO (HR 0.37; 95% CI 0.14 - 0.96).	3.6 years	22/24
Tiller, 2002 ³⁹	Australia	Prospective cohort	83	BRCA1/BRCA2 carriers or at increased risk because of FH of OC	RRSO	HRT uptake	HRT uptake post RRSO 82%	3 years	24/24
Tucker, 2016 ⁶⁰	Australia	Cross-sectional	119	BRCA1/BRCA2	RRSO	HRT efficacy	The risk of sexual dysfunction in those	NR	20/24

				carriers or strong FH of OC			participants using topical vaginal oestrogen was 84% less than those not using it. Greater QoL with HRT use vs no use (p=0.010)		
Vermeulen, 2017 ⁶¹	Netherlands	Prospective cohort	57	BRCA1/BRCA2 carriers	RRSO	HRT uptake	Pre-menopausal HRT uptake: 47% (27/57)	9 months	22/24

NR – not reported, RRSO – risk reducing salpingo-oophorectomy, RRESDO – risk reducing early salpingectomy with delayed oophorectomy, OC – ovarian cancer, QoL – quality of life, HRT – hormone replacement therapy, DEXA - dual-energy X-ray absorptiometry

Journal Pre-proof

1. Antill Y, Reynolds J, Young MA, Kirk J, Tucker K, Bogtstra T, et al. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. *European journal of cancer (Oxford, England : 1990)*. 2006 Mar;42(5):621-8.
2. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. *Genetic testing and molecular biomarkers*. 2009 Feb 2009;13(1):51-6.
3. Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. *American journal of medical genetics Part A*. 2003 Apr 30;118a(3):201-9.
4. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. *Genetics in medicine : official journal of the American College of Medical Genetics*. 2008 Mar 2008;10(3):161-6.
5. Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. *Breast cancer research and treatment*. 2014;148(2):397-406.
6. Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. *Cancer*. 2017;123(13):2497-505.
7. D'Alonzo M, Pecchio S, Liberale V, Modaffari P, Biglia N, Piva E, et al. Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. *Clinical Breast Cancer*. 2018 Dec 2018;18(6).
8. Evans DG, Laloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2009 Aug;18(8):2318-24.
9. Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(12):1321-8.
10. Flippo-Morton T, Walsh K, Sarantou T, White RL, Chambers K, Amacker-North L, et al. Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature. *Breast Journal*. 2016 Jan 2016;22(1):35-44.
11. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. *Clin Breast Cancer*. 2007 Dec;7(11):875-82.
12. Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, et al. Risk management options elected by women after testing positive for a BRCA mutation. *Gynecol Oncol*. 2014 Feb;132(2):428-33.
13. Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D. Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia. *Current oncology (Toronto, Ont)*. 2019 Feb;26(1):e17-e23.
14. Harmsen MG, Arts-de Jong M, Horstik K, Manders P, Massuger L, Hermens R, et al. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. *Gynecol Oncol*. 2016 Oct;143(1):113-9.

15. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. *Gynecologic oncology*. 2014 May 2014;133(2):283-6.
16. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med*. 2002 May 23;346(21):1609-15.
17. Kim SI, Lim MC, Lee DO, Seo SS, Kang S, Park SY, et al. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. *Journal of Cancer Research and Clinical Oncology*. 2016 Jan 2016;142(1):333-40.
18. Kram V, Peretz T, Sagi M. Acceptance of Preventive Surgeries by Israeli Women Who had Undergone BRCA Testing. *Familial Cancer*. 2006 2006/11/01;5(4):327-35.
19. Kwong A, Wong CH, Shea C, Suen DT, Choi CL. Choice of management of southern Chinese BRCA mutation carriers. *World journal of surgery*. 2010 Jul;34(7):1416-26.
20. Laitman Y, Vaisman Y, Feldman D, Helpman L, Gitly M, Paluch Shimon S, et al. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. *Clinical genetics*. 2014 Jan;85(1):68-71.
21. Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. *Preventive medicine*. 2000 Jul;31(1):75-80.
22. Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JGM, Seynaeve C, et al. One Year Follow-Up of Women Opting for Presymptomatic Testing for BRCA1 and BRCA2: Emotional Impact of the Test Outcome and Decisions on Risk Management (Surveillance or Prophylactic Surgery). *Breast Cancer Research and Treatment*. 2002 2002/05/01;73(2):97-112.
23. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. *J Clin Oncol*. 2005 Oct 1;23(28):6890-8.
24. Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic oncology*. 2017;145(1):122-9.
25. Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. *Bjog*. 2012 Jan 20.
26. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. *Lancet (London, England)*. 2000 Jun 10;355(9220):2015-20.
27. Metcalfe KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. *Journal of medical genetics*. 2000 Nov 2000;37(11):866-74.
28. Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, et al. Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. *Open medicine : a peer-reviewed, independent, open-access journal*. 2007;1(2):e92-e8.
29. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. *Br J Cancer*. 2019 Jul;121(1):15-21.

30. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. *Gynecologic oncology*. 2018;150(1):79-84.
31. Pezaro C, James P, McKinley J, Shanahan M, Young MA, Mitchell G. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. *Fam Cancer*. 2012 Sep;11(3):403-10.
32. Phillips KA, Jenkins MA, Lindeman GJ, McLachlan SA, McKinley JM, Weideman PC, et al. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Clinical genetics*. 2006 Sep;70(3):198-206.
33. Ray JA, Loescher LJ, Brewer M. Risk-reduction surgery decisions in high-risk women seen for genetic counseling. *Journal of genetic counseling*. 2005 Dec 2005;14(6):473-84.
34. Julian-Reynier C, Mancini J, Mouret-Fourme E, Gauthier-Villars M, Bonadona V, Berthet P, et al. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. *European journal of human genetics : EJHG*. 2011 May;19(5):500-6.
35. Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. *Cancer*. 2012 Jan 15;118(2):510-7.
36. Sidon L, Ingham S, Clancy T, Clayton R, Clarke A, Jones EA, et al. Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. *Br J Cancer*. 2012 Feb 14;106(4):775-9.
37. Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. *American journal of obstetrics and gynecology*. 2013 Apr;208(4):329.e1-6.
38. Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brondum-Nielsen K, Waldstrom M, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. *Clinical genetics*. 2010 Apr;77(4):342-9.
39. Tiller K, Meiser B, Butow P, Clifton M, Thewes B, Friedlander M, et al. Psychological Impact of Prophylactic Oophorectomy in Women at Increased Risk of Developing Ovarian Cancer: A Prospective Study. *Gynecologic Oncology*. 2002 2002/08/01/;86(2):212-9.
40. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. *Cancer*. 2006 Dec 15;107(12):2745-51.
41. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, et al. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. *Cancer*. 2011 Jun 2011;117(12):2659-67.
42. Challberg J, Ashcroft L, Laloo F, Eckersley B, Clayton R, Hopwood P, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. *British journal of cancer*. 2011;105(1):22-7.
43. Chapman JS, Powell CB, McLennan J, Crawford B, Mak J, Stewart N, et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. *Gynecol Oncol*. 2011 Aug;122(2):339-43.
44. Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. *Fam Cancer*. 2012 Mar;11(1):69-75.
45. Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, et al. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. *European journal of cancer (Oxford, England : 1990)*. 2015 Feb;51(3):400-8.

46. Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, et al. Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. *PLoS one*. 2017;12(1):e0169673.
47. Garcia C, Lyon L, Conell C, Littell RD, Powell CB. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy. *Gynecol Oncol*. 2015 Sep;138(3):723-6.
48. Michelsen TM, Dørum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. *Gynecologic Oncology*. 2009 2009/04/01/;113(1):128-33.
49. Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study. *European Journal of Cancer*. 2009;45(1):82-9.
50. Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010 Feb;20(2):233-9.
51. Powell CB, Alabaster A, Stoller N, Armstrong MA, Salyer C, Hamilton I, et al. Bone loss in women with BRCA1 and BRCA2 mutations. *Gynecol Oncol*. 2018 Mar;148(3):535-9.
52. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. *Journal of the National Cancer Institute*. 2008 Oct 1;100(19):1361-7.
53. Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. *Gynecologic Oncology*. 2011 2011/04/01/;121(1):163-8.
54. Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. *Psycho-oncology*. 2013 Jan;22(1):212-9.
55. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. *Gynecologic oncology*. 2016 Jan 2016;140(1):101-6.
56. Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. *Breast Cancer Res Treat*. 2016 Jan;155(2):365-73.
57. Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. *JAMA Oncol*. 2018 Aug 1;4(8):1059-65.
58. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. *J Clin Oncol*. 2006 Aug 1;24(22):3576-82.
59. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol*. 2005 Nov 1;23(31):7804-10.
60. Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy. *Maturitas*. 2016 Mar;85:42-8.

61. Vermeulen RFM, Beurden Mv, Kieffer JM, Bleiker EMA, Valdimarsdottir HB, Massuger LFAG, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. *European Journal of Cancer*. 2017 2017/10/01/;84:159-67.

Journal Pre-proof

HIGHLIGHTS

- Acceptability of surgical prevention of ovarian-cancer in BRCA-carriers is a dynamic concept.
- Acceptability is influenced by counselling on health outcomes after surgery and HRT safety.
- Premenopausal oophorectomy increases risk of osteoporosis, heart-disease, neurocognitive-decline.
- HRT use until natural-menopause mitigates risks and data supports safety of short term use in *BRCA*-carriers.

Journal Pre-proof